Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
8-HOUR BAYER vs CAPREOMYCIN SULFATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Irreversibly acetylates cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), inhibiting prostaglandin and thromboxane A2 synthesis, leading to analgesic, antipyretic, anti-inflammatory, and antiplatelet effects.
Inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, causing misreading of m RNA and inhibiting translation initiation. Also alters membrane permeability.
Relief of pain, fever, and inflammation,Reduction of risk of myocardial infarction in patients with previous MI or unstable angina,Prevention of recurrent ischemic stroke or transient ischemic attack
Treatment of pulmonary tuberculosis as part of combination therapy,Salvage therapy for multidrug-resistant tuberculosis
325-650 mg every 8 hours for pain/fever; 81-325 mg daily for cardiovascular prophylaxis.
15 mg/kg (up to 1 g) intramuscularly or intravenously once daily for 60 days, then 15 mg/kg (up to 1 g) 2-3 times weekly for 12-18 months in combination with other antituberculosis agents.
15-20 hours (terminal elimination half-life) for salicylate at therapeutic concentrations; prolonged to 20-30 hours at high doses due to saturation of hepatic metabolism (zero-order kinetics).
Terminal elimination half-life: 24-40 hours (prolonged in renal impairment; anuria may extend to 96-120 hours).
Hepatic hydrolysis by esterases to salicylic acid, which is primarily conjugated in the liver via glucuronidation and glycine conjugation (salicyluric acid), with minor oxidation by cytochrome P450 (CYP2C9) to gentisic acid.
Not significantly metabolized; primarily excreted unchanged in urine via glomerular filtration.
Renal excretion of conjugated salicylate metabolites (75% as salicyluric acid, 10% as salicyl phenolic glucuronide, 5% as salicyl acyl glucuronide, 5% as gentisic acid); 10% free salicylate; approximately 10% eliminated in feces via bile.
Primarily renal (80-90% as unchanged drug via glomerular filtration). Biliary/fecal elimination: <1%.
80-90% bound to albumin; binding is concentration-dependent and saturable.
Approximately 30% bound to serum proteins (albumin).
0.15-0.2 L/kg for salicylate; distributes into synovial fluid, CNS, and placental tissues; Vd increases in acidosis.
0.4-0.6 L/kg (suggests distribution primarily into extracellular fluid; poor CNS penetration unless meninges inflamed).
Oral: Approximately 100% for immediate-release, but extended-release may have slightly reduced absorption (relative bioavailability 85-90% compared to immediate-release).
IM: 100% (only IM route available; no oral formulation).
Avoid in severe renal impairment (Cr Cl <30 m L/min). Use with caution and monitor for bleeding in moderate impairment. Reduce dose or extend interval.
Cr Cl 50-80 m L/min: 15 mg/kg every 24-36 hours; Cr Cl 30-50 m L/min: 15 mg/kg every 48 hours; Cr Cl 10-30 m L/min: 15 mg/kg every 72 hours; Cr Cl <10 m L/min: 15 mg/kg every 96-120 hours.
Avoid in severe hepatic impairment. Use with caution in moderate impairment; monitor liver function.
No dose adjustment required for hepatic impairment; monitor for hepatotoxicity.
Not recommended in children <12 years for viral infections due to Reye's syndrome risk (contraindicated).
15-30 mg/kg intramuscularly or intravenously once daily (maximum 1 g) for 60 days, then 15-30 mg/kg 2-3 times weekly (maximum 1 g).
Increased risk of GI bleeding and renal impairment; use lowest effective dose, monitor renal function and signs of bleeding.
Initiate at lower end of dosing range; adjust based on renal function due to age-related decline in glomerular filtration rate.
None
None officially listed by FDA; however, use with caution due to potential nephrotoxicity and ototoxicity.
Increased risk of gastrointestinal bleeding and ulceration; Reye syndrome in children with viral illness; Hemorrhagic stroke risk with high doses; Impaired renal function in predisposed patients; Bronchospasm in aspirin-sensitive asthma; Anaphylactic reactions; Use caution in patients with hepatic impairment or G6PD deficiency.
Nephrotoxicity: Monitor renal function; risk increases with cumulative dose and concomitant nephrotoxic drugs.,Ototoxicity: Can cause vestibular and cochlear damage, especially in patients with renal impairment.,Neuromuscular blockade: May exacerbate weakness in patients with myasthenia gravis or other neuromuscular disorders.,Electrolyte disturbances: Hypokalemia, hypocalcemia, and hypomagnesemia due to renal tubular effects.
Known hypersensitivity to NSAIDs or aspirin; Active peptic ulcer disease or GI bleeding; Severe renal impairment (e GFR <30 m L/min); Hemorrhagic diathesis; Children with viral infection (Reye syndrome); Third trimester of pregnancy; Severe hepatic impairment.
Hypersensitivity to capreomycin or any component,Pre-existing severe renal impairment (Cr Cl < 30 m L/min) unless benefit outweighs risk,Pre-existing hearing loss
Avoid alcohol; may increase risk of gastrointestinal bleeding. No specific food restrictions, but taking with food can reduce gastric irritation. Avoid high-dose vitamin C supplements as they may increase salicylate levels.
No specific food interactions. However, maintain adequate hydration and electrolyte-rich diet (bananas, potatoes) to mitigate hypokalemia.
First trimester: No well-controlled studies. Avoid use unless clearly needed. Second and third trimesters: Aspirin should be avoided due to risk of premature closure of ductus arteriosus, oligohydramnios, and increased risk of maternal and fetal bleeding. High doses may cause constriction of ductus arteriosus in utero and persistent pulmonary hypertension in newborn.
Animal studies suggest embryotoxicity and teratogenicity; human data limited. Avoid in first trimester; use in second and third trimesters only if clearly needed. Risk of ototoxicity and nephrotoxicity to fetus.
Small amounts of aspirin are excreted in breast milk. M/P ratio not established. Use with caution in breastfeeding women; avoid high doses due to risk of Reye's syndrome in infants and potential for adverse effects on platelet function.
Small amounts excreted in breast milk; not expected to cause adverse effects in infants due to poor oral absorption. M/P ratio unknown.
Pregnancy increases clearance of aspirin; however, dose adjustments are not routinely recommended due to narrow therapeutic index. Use lowest effective dose for shortest duration. Avoid in third trimester.
No dose adjustment recommended for pregnancy alone; however, concurrent use may require monitoring and adjustment. No pharmacokinetic changes reported.
8-Hour Bayer is enteric-coated aspirin designed for extended release, reducing gastrointestinal irritation. Onset of action is delayed; not suitable for acute pain or rapid antiplatelet effect. Use with caution in patients with history of peptic ulcer disease or on anticoagulants. Monitor renal function in elderly or dehydrated patients. Avoid in children with viral illness due to Reye's syndrome risk.
Capreomycin is a second-line injectable agent for multidrug-resistant tuberculosis (MDR-TB). Monitor for nephrotoxicity (creatinine, BUN) and ototoxicity (audiometry, vestibular testing). Electrolyte disturbances (hypokalemia, hypomagnesemia) are common; replace aggressively. Administer deep IM injection; rotate sites. Contraindicated in pregnancy (teratogenic). Synergistic with other antituberculars; never use as monotherapy.
Take with a full glass of water; do not crush or chew the tablet.,Do not use within 7 days before surgery due to bleeding risk.,If used for pain, consult a doctor if symptoms persist for more than 10 days.,Avoid alcohol while taking this medication to reduce stomach bleeding risk.,Seek medical attention for signs of bleeding (black stools, blood in vomit).
Take exactly as prescribed; do not skip doses to prevent resistance.,Report hearing loss, ringing in ears, or dizziness immediately.,Report decreased urine output, swelling, or unusual fatigue.,You will need regular blood tests (kidney function, electrolyte levels).,Avoid alcohol and excessive salt intake.,Contact your doctor if you develop severe injection site pain or fever.
No interactions on record
"Decamethonium, a depolarizing neuromuscular blocker, and capreomycin, an aminoglycoside antibiotic, synergistically prolong neuromuscular blockade. Capreomycin decreases acetylcholine release at the motor endplate, while decamethonium persistently depolarizes the postsynaptic membrane, leading to enhanced and prolonged muscle relaxation. This interaction can result in extended respiratory depression and apnea, particularly during anesthesia or in critically ill patients."
"Streptozocin, a nitrosourea alkylating agent, may potentiate the neuromuscular blocking effects of capreomycin, a cyclic polypeptide antibiotic that inhibits neuromuscular transmission by reducing acetylcholine release at the motor endplate. This interaction can lead to prolonged or enhanced muscle weakness, including respiratory depression, particularly in patients with underlying neuromuscular disorders (e.g., myasthenia gravis) or those receiving other neuromuscular blocking agents. The clinical outcome may range from mild skeletal muscle weakness to severe respiratory compromise requiring mechanical ventilation."
"Paromomycin, an aminoglycoside antibiotic, and capreomycin, a polypeptide antibiotic, both possess neuromuscular blocking properties. Their co-administration can result in additive or synergistic neuromuscular blockade, potentially leading to prolonged or enhanced muscle relaxation, respiratory depression, or apnea. This interaction is particularly dangerous in patients receiving general anesthetics, neuromuscular blocking agents, or those with underlying neuromuscular disorders such as myasthenia gravis."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about 8-HOUR BAYER vs CAPREOMYCIN SULFATE, answered by our medical review team.
8-HOUR BAYER is a NSAID that works by Irreversibly acetylates cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), inhibiting prostaglandin and thromboxane A2 synthesis, leading to analgesic, antipyretic, anti-inflammatory, and antiplatelet effects.. CAPREOMYCIN SULFATE is a Antitubercular Agent that works by Inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, causing misreading of m RNA and inhibiting translation initiation. Also alters membrane permeability.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between 8-HOUR BAYER and CAPREOMYCIN SULFATE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of 8-HOUR BAYER is: 325-650 mg every 8 hours for pain/fever; 81-325 mg daily for cardiovascular prophylaxis.. The standard adult dose of CAPREOMYCIN SULFATE is: 15 mg/kg (up to 1 g) intramuscularly or intravenously once daily for 60 days, then 15 mg/kg (up to 1 g) 2-3 times weekly for 12-18 months in combination with other antituberculosis agents.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between 8-HOUR BAYER and CAPREOMYCIN SULFATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. 8-HOUR BAYER is classified as Category C. First trimester: No well-controlled studies. Avoid use unless clearly needed. Second and third trimesters: Aspirin should be avoided due to risk of premature closure of ductus arte. CAPREOMYCIN SULFATE is classified as Category C. Animal studies suggest embryotoxicity and teratogenicity; human data limited. Avoid in first trimester; use in second and third trimesters only if clearly needed. Risk of ototoxici. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.